Evaluating Datopotamab Deruxtecan With or Without Durvalumab Versus Chemotherapy Plus Pembrolizumab for PD-L1 Positive Locally Recurrent or Metastatic Triple-negative Breast Cancer
Led by AstraZeneca · Updated on 2026-09-25
625
Participants Needed
318
Research Sites
165 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life.
Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months.
During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
CONDITIONS
Brief Title
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Research Team
A
AstraZeneca Clinical Study Information Center
A
AstraZeneca Breast Cancer Study Locator Service
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Dato-DXd with durvalumab
Chemotherapy (ICC) plus pembrolizumab
Dato-DXd alone
What it is
An investigational combination of Dato-DXd (a TROP2-directed antibody-drug conjugate) and durvalumab (a PD-L1 inhibitor), both given by intravenous infusion.
A standard-of-care regimen of investigator's choice chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) combined with pembrolizumab (a PD-1 inhibitor), all given by intravenous infusion.
Investigational Dato-DXd (a TROP2-directed antibody-drug conjugate) given alone by intravenous infusion.
Role in trial
Test arm for evaluating the efficacy and safety of Dato-DXd combined with durvalumab.
Control arm representing current standard practice in PD-L1-high metastatic triple-negative breast cancer.
Test arm evaluating Dato-DXd monotherapy as an alternative novel approach.
Primary use in this trial
Being evaluated for first-line treatment of locally recurrent inoperable or metastatic triple-negative breast cancer with high PD-L1 expression.
Standard first-line treatment for eligible patients with advanced PD-L1-high triple-negative breast cancer.
Being evaluated as a novel monotherapy option for the same patient population.
How it is given or performed
Dato-DXd and durvalumab are both administered as intravenous infusions in clinic.
Chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) and pembrolizumab are administered intravenously. Regimen selected per investigator and guideline practice.
Dato-DXd is administered as an intravenous infusion in the clinic.
Evidence status (published/ongoing)
Ongoing study, no published outcome data yet. Initial protocol and rationale published, but results are pending.
Multiple studies and guidelines support chemotherapy plus pembrolizumab as standard first-line therapy for PD-L1-high triple-negative breast cancer.
Ongoing study, published outcomes for Dato-DXd monotherapy in this population are not yet available.
Important limitations
Patient outcomes, including survival and safety, are not yet established as the trial is ongoing. Combination therapy may introduce additional risks or interactions.
Chemotherapy in combination with immunotherapy can cause immune-related and chemotherapy-related adverse effects; regimen selection and tolerance may vary based on patient factors.
As an investigational monotherapy, Dato-DXd lacks established survival, safety, and comparative efficacy data in this setting.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Histologically or cytologically confirmed locally recurrent inoperable or metastatic triple-negative breast cancer as per ASCO-CAP guidelines
ECOG performance status of 0 or 1
Provide a tumor sample collected from locally recurrent inoperable or metastatic tumor or an archival sample collected within 3 years before consent
PD-L1 positive status with CPS score of 10 or higher confirmed by sponsor-designated central lab using PD-L1 (22C3) assay
No prior chemotherapy or systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer
For patients with recurrent disease, at least 6 months must have passed since completion of treatment with curative intent
Eligible for one of the chemotherapy options: paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin
Measurable disease according to RECIST 1.1
Adequate bone marrow reserve and organ function
Male and female participants of childbearing potential must agree to use specified contraception methods
You will not qualify if you...
Presence of severe or uncontrolled medical conditions judged by investigator to make participation unsafe or affect protocol compliance
History of another primary cancer unless treated with curative intent and no active disease within 2 years prior to study start
History of treated neoplastic spinal cord compression or inactive brain metastases without symptoms and no corticosteroid or anticonvulsant treatment needed
Uncontrolled infections requiring intravenous antibiotics, antivirals, or antifungals
Active or uncontrolled hepatitis B or C
Known uncontrolled HIV infection
Uncontrolled or significant cardiac disease
History or current interstitial lung disease or pneumonitis requiring steroids or suspected but not ruled out by imaging
Severe pulmonary function impairment
Significant corneal disease
Active or prior autoimmune or inflammatory disorders
Prior treatment with ADC containing topoisomerase I or TROP2-targeted therapy
Current use of any anti-cancer treatment
Known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd
Currently pregnant, breastfeeding, or planning pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 33 months
Participants receive assigned study treatments: Dato-DXd with durvalumab, Dato-DXd alone, or chemotherapy plus pembrolizumab through intravenous infusions.
Regular visits for treatment and assessments
Follow-up
Duration - Up to 64 months from randomization
Participants are monitored for long-term outcomes including progression-free survival, overall survival, response rates, quality of life, and safety.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Peter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy...